Filing Details
- Accession Number:
- 0001493152-20-018389
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-09-25 21:30:10
- Reporting Period:
- 2020-09-23
- Accepted Time:
- 2020-09-25 21:30:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1394319 | Tracon Pharmaceuticals Inc. | TCON | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1595855 | Opaleye Management Inc. | One Boston Place, 26Th Floor Boston MA 02108 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, Par Value $0.001 Per Share | Acquisiton | 2020-09-23 | 2,200 | $4.83 | 227,466 | No | 4 | P | Indirect | By Managed Account |
| Common Stock, Par Value $0.001 Per Share | Acquisiton | 2020-09-23 | 55,000 | $4.83 | 1,764,438 | No | 4 | P | Indirect | By Opaleye, L.P. |
| Common Stock, Par Value $0.001 Per Share | Acquisiton | 2020-09-24 | 534 | $4.44 | 228,000 | No | 4 | P | Indirect | By Managed Account |
| Common Stock, Par Value $0.001 Per Share | Acquisiton | 2020-09-24 | 21,000 | $4.44 | 1,785,438 | No | 4 | P | Indirect | By Opaleye, L.P. |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | By Managed Account |
| No | 4 | P | Indirect | By Opaleye, L.P. |
| No | 4 | P | Indirect | By Managed Account |
| No | 4 | P | Indirect | By Opaleye, L.P. |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Pre-funded warrant | $0.01 | 2020-08-27 | 2027-08-27 | 1,889,513 | 1,889,513 | Indirect |
| Common Stock | Pre-funded warrant | $0.01 | 2020-08-31 | 2027-08-31 | 1,358,993 | 1,358,993 | Indirect |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2027-08-27 | 1,889,513 | 1,889,513 | Indirect |
| 2027-08-31 | 1,358,993 | 1,358,993 | Indirect |
Footnotes
- The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $4.833. The range of purchase prices on the transaction date was $4.71 to $4.90 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
- Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
- Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
- The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $4.4417. The range of purchase prices on the transaction date was $4.11 to $4.91 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
- The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 9.99% of the Issuer's then outstanding common stock.
Billionaire Hedge Funds
